Incyte Corporation (0J9P.L)
USD 69.2
(0.13%)
USD 69.2
(0.13%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 1.59 Billion USD | 8.25% |
| 2022 | 1.47 Billion USD | 26.43% |
| 2021 | 1.16 Billion USD | 22.5% |
| 2020 | 949.65 Million USD | 14.64% |
| 2019 | 828.34 Million USD | 15.08% |
| 2018 | 719.79 Million USD | 7.12% |
| 2017 | 671.95 Million USD | -44.88% |
| 2016 | 1.21 Billion USD | 45.78% |
| 2015 | 836.28 Million USD | 0.75% |
| 2014 | 830.06 Million USD | 31.85% |
| 2013 | 629.56 Million USD | 90.54% |
| 2012 | 330.41 Million USD | -40.58% |
| 2011 | 556.03 Million USD | -3.84% |
| 2010 | 578.22 Million USD | -29.03% |
| 2009 | 814.77 Million USD | 79.81% |
| 2008 | 453.13 Million USD | 4.12% |
| 2007 | 435.21 Million USD | -0.75% |
| 2006 | 438.51 Million USD | 11.44% |
| 2005 | 393.5 Million USD | -10.24% |
| 2004 | 438.4 Million USD | 94.66% |
| 2003 | 225.21 Million USD | -9.82% |
| 2002 | 249.72 Million USD | -5.89% |
| 2001 | 265.35 Million USD | 0.47% |
| 2000 | 264.12 Million USD | 411.87% |
| 1999 | 51.6 Million USD | 1.78% |
| 1998 | 50.7 Million USD | 7.64% |
| 1997 | 47.1 Million USD | 117.05% |
| 1996 | 21.7 Million USD | 97.27% |
| 1995 | 11 Million USD | 134.04% |
| 1994 | 4.7 Million USD | 213.33% |
| 1993 | 1.5 Million USD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 1.74 Billion USD | 9.36% |
| 2024 Q3 | 1.84 Billion USD | 10.6% |
| 2024 Q2 | 1.66 Billion USD | -4.4% |
| 2023 Q3 | 1.45 Billion USD | -0.73% |
| 2023 Q2 | 1.46 Billion USD | 9.93% |
| 2023 Q1 | 1.33 Billion USD | -9.23% |
| 2023 FY | 1.59 Billion USD | 8.25% |
| 2023 Q4 | 1.59 Billion USD | 9.3% |
| 2022 Q2 | 1.23 Billion USD | 3.6% |
| 2022 Q1 | 1.19 Billion USD | 2.39% |
| 2022 FY | 1.47 Billion USD | 26.43% |
| 2022 Q4 | 1.47 Billion USD | 14.59% |
| 2022 Q3 | 1.28 Billion USD | 4.02% |
| 2021 Q3 | 1.05 Billion USD | 8.4% |
| 2021 Q4 | 1.16 Billion USD | 10.78% |
| 2021 FY | 1.16 Billion USD | 22.5% |
| 2021 Q1 | 933.59 Million USD | -1.69% |
| 2021 Q2 | 968.76 Million USD | 3.77% |
| 2020 FY | 949.65 Million USD | 14.64% |
| 2020 Q1 | 814.7 Million USD | -1.65% |
| 2020 Q2 | 867.71 Million USD | 6.51% |
| 2020 Q3 | 916.59 Million USD | 5.63% |
| 2020 Q4 | 949.65 Million USD | 3.61% |
| 2019 Q3 | 792.29 Million USD | 13.11% |
| 2019 Q4 | 828.34 Million USD | 4.55% |
| 2019 FY | 828.34 Million USD | 15.08% |
| 2019 Q1 | 668.59 Million USD | -7.11% |
| 2019 Q2 | 700.44 Million USD | 4.76% |
| 2018 Q4 | 719.79 Million USD | 0.38% |
| 2018 FY | 719.79 Million USD | 7.12% |
| 2018 Q1 | 677.96 Million USD | 0.9% |
| 2018 Q2 | 664.23 Million USD | -2.03% |
| 2018 Q3 | 717.04 Million USD | 7.95% |
| 2017 Q1 | 641.41 Million USD | -47.39% |
| 2017 FY | 671.95 Million USD | -44.88% |
| 2017 Q4 | 671.95 Million USD | 8.99% |
| 2017 Q3 | 616.55 Million USD | 0.64% |
| 2017 Q2 | 612.6 Million USD | -4.49% |
| 2016 FY | 1.21 Billion USD | 45.78% |
| 2016 Q1 | 876.19 Million USD | 4.77% |
| 2016 Q4 | 1.21 Billion USD | 3.83% |
| 2016 Q3 | 1.17 Billion USD | 4.75% |
| 2016 Q2 | 1.12 Billion USD | 27.93% |
| 2015 Q2 | 875.16 Million USD | -3.19% |
| 2015 FY | 836.28 Million USD | 0.75% |
| 2015 Q4 | 836.28 Million USD | -0.82% |
| 2015 Q1 | 904.03 Million USD | 8.91% |
| 2015 Q3 | 843.19 Million USD | -3.65% |
| 2014 Q2 | 850.1 Million USD | 27.49% |
| 2014 Q4 | 830.06 Million USD | -5.12% |
| 2014 Q1 | 666.82 Million USD | 5.92% |
| 2014 Q3 | 874.85 Million USD | 2.91% |
| 2014 FY | 830.06 Million USD | 31.85% |
| 2013 Q4 | 629.56 Million USD | 91.59% |
| 2013 FY | 629.56 Million USD | 90.54% |
| 2013 Q1 | 493.8 Million USD | 49.45% |
| 2013 Q2 | 362 Million USD | -26.69% |
| 2013 Q3 | 328.6 Million USD | -9.23% |
| 2012 Q4 | 330.41 Million USD | -36.03% |
| 2012 FY | 330.41 Million USD | -40.58% |
| 2012 Q1 | 542.45 Million USD | -2.44% |
| 2012 Q2 | 529.15 Million USD | -2.45% |
| 2012 Q3 | 516.48 Million USD | -2.4% |
| 2011 Q2 | 552.94 Million USD | -1.89% |
| 2011 FY | 556.03 Million USD | -3.84% |
| 2011 Q4 | 556.03 Million USD | 0.69% |
| 2011 Q3 | 552.24 Million USD | -0.13% |
| 2011 Q1 | 563.58 Million USD | -2.53% |
| 2010 Q1 | 617.07 Million USD | -24.26% |
| 2010 FY | 578.22 Million USD | -29.03% |
| 2010 Q4 | 578.22 Million USD | -2.58% |
| 2010 Q3 | 593.54 Million USD | -0.82% |
| 2010 Q2 | 598.46 Million USD | -3.02% |
| 2009 FY | 814.77 Million USD | 79.81% |
| 2009 Q1 | 446.38 Million USD | -1.49% |
| 2009 Q3 | 672.17 Million USD | 49.22% |
| 2009 Q2 | 450.44 Million USD | 0.91% |
| 2009 Q4 | 814.77 Million USD | 21.22% |
| 2008 Q4 | 453.13 Million USD | 2.5% |
| 2008 Q1 | 434.05 Million USD | -0.26% |
| 2008 Q2 | 441.93 Million USD | 1.81% |
| 2008 Q3 | 442.09 Million USD | 0.04% |
| 2008 FY | 453.13 Million USD | 4.12% |
| 2007 FY | 435.21 Million USD | -0.75% |
| 2007 Q1 | 429.41 Million USD | -2.08% |
| 2007 Q3 | 424.15 Million USD | -1.0% |
| 2007 Q4 | 435.21 Million USD | 2.61% |
| 2007 Q2 | 428.43 Million USD | -0.23% |
| 2006 Q3 | 531.03 Million USD | 23.54% |
| 2006 Q1 | 436.52 Million USD | 10.93% |
| 2006 Q4 | 438.51 Million USD | -17.42% |
| 2006 FY | 438.51 Million USD | 11.44% |
| 2006 Q2 | 429.83 Million USD | -1.53% |
| 2005 FY | 393.5 Million USD | -10.24% |
| 2005 Q1 | 427.59 Million USD | -2.47% |
| 2005 Q2 | 402.89 Million USD | -5.78% |
| 2005 Q3 | 394.59 Million USD | -2.06% |
| 2005 Q4 | 393.5 Million USD | -0.28% |
| 2004 FY | 438.4 Million USD | 94.66% |
| 2004 Q1 | 464.65 Million USD | 106.32% |
| 2004 Q2 | 485.48 Million USD | 4.48% |
| 2004 Q4 | 438.4 Million USD | -0.31% |
| 2004 Q3 | 439.74 Million USD | -9.42% |
| 2003 Q1 | 232.86 Million USD | -6.75% |
| 2003 FY | 225.21 Million USD | -9.82% |
| 2003 Q4 | 225.21 Million USD | 1.73% |
| 2003 Q3 | 221.37 Million USD | -5.04% |
| 2003 Q2 | 233.11 Million USD | 0.11% |
| 2002 Q4 | 249.72 Million USD | 7.38% |
| 2002 FY | 249.72 Million USD | -5.89% |
| 2002 Q1 | 245.43 Million USD | -7.51% |
| 2002 Q2 | 241.46 Million USD | -1.62% |
| 2002 Q3 | 232.57 Million USD | -3.68% |
| 2001 Q4 | 265.35 Million USD | 9.56% |
| 2001 FY | 265.35 Million USD | 0.47% |
| 2001 Q1 | 241.88 Million USD | -8.42% |
| 2001 Q2 | 247.77 Million USD | 2.43% |
| 2001 Q3 | 242.2 Million USD | -2.25% |
| 2000 Q2 | 274.69 Million USD | 1.22% |
| 2000 Q1 | 271.37 Million USD | 425.91% |
| 2000 FY | 264.12 Million USD | 411.87% |
| 2000 Q3 | 256.43 Million USD | -6.65% |
| 2000 Q4 | 264.12 Million USD | 3.0% |
| 1999 FY | 51.6 Million USD | 1.78% |
| 1999 Q1 | 73.2 Million USD | 44.38% |
| 1999 Q2 | 53.3 Million USD | -27.19% |
| 1999 Q3 | 44.1 Million USD | -17.26% |
| 1999 Q4 | 51.6 Million USD | 17.01% |
| 1998 Q4 | 50.7 Million USD | -11.52% |
| 1998 Q3 | 57.3 Million USD | -6.53% |
| 1998 FY | 50.7 Million USD | 7.64% |
| 1998 Q2 | 61.3 Million USD | -9.59% |
| 1998 Q1 | 67.8 Million USD | 43.95% |
| 1997 FY | 47.1 Million USD | 117.05% |
| 1997 Q1 | 33.3 Million USD | 53.46% |
| 1997 Q2 | 27.1 Million USD | -18.62% |
| 1997 Q3 | 40 Million USD | 47.6% |
| 1997 Q4 | 47.1 Million USD | 17.75% |
| 1996 Q4 | 21.7 Million USD | -27.42% |
| 1996 Q3 | 29.9 Million USD | 32.3% |
| 1996 Q2 | 22.6 Million USD | 31.4% |
| 1996 Q1 | 17.2 Million USD | 56.36% |
| 1996 FY | 21.7 Million USD | 97.27% |
| 1995 FY | 11 Million USD | 134.04% |
| 1995 Q2 | 3.8 Million USD | -19.15% |
| 1995 Q3 | 3.6 Million USD | -5.26% |
| 1995 Q4 | 11 Million USD | 205.56% |
| 1995 Q1 | 4.7 Million USD | 0.0% |
| 1994 FY | 4.7 Million USD | 213.33% |
| 1994 Q1 | 1.3 Million USD | -13.33% |
| 1994 Q2 | 1.7 Million USD | 30.77% |
| 1994 Q3 | 1.5 Million USD | -11.76% |
| 1994 Q4 | 4.7 Million USD | 213.33% |
| 1993 Q3 | 1.1 Million USD | 0.0% |
| 1993 Q4 | 1.5 Million USD | 36.36% |
| 1993 FY | 1.5 Million USD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Editas Medicine, Inc. | 150.05 Million USD | -961.117% |
| Dynavax Technologies Corporation | 375.02 Million USD | -324.578% |
| Supernus Pharmaceuticals, Inc. | 487.46 Million USD | -226.646% |
| Perrigo Company plc | 6.04 Billion USD | 73.643% |
| Illumina, Inc. | 4.36 Billion USD | 63.53% |
| Thermo Fisher Scientific Inc. | 51.88 Billion USD | 96.931% |
| Iovance Biotherapeutics, Inc. | 195.73 Million USD | -713.47% |
| Walgreens Boots Alliance, Inc. | 68.85 Billion USD | 97.688% |
| IQVIA Holdings Inc. | 20.56 Billion USD | 92.259% |
| Heron Therapeutics, Inc. | 256.47 Million USD | -520.819% |
| Regeneron Pharmaceuticals, Inc. | 7.1 Billion USD | 77.596% |
| Unity Biotechnology, Inc. | 37.29 Million USD | -4169.736% |
| Waters Corporation | 3.47 Billion USD | 54.199% |
| Biogen Inc. | 12.04 Billion USD | 86.781% |
| Sangamo Therapeutics, Inc. | 82.43 Million USD | -1831.593% |
| Evolus, Inc. | 209.68 Million USD | -659.356% |
| Adicet Bio, Inc. | 37.12 Million USD | -4189.52% |
| Cara Therapeutics, Inc. | 68.75 Million USD | -2215.726% |
| bluebird bio, Inc. | 424.62 Million USD | -274.984% |
| Esperion Therapeutics, Inc. | 660.79 Million USD | -140.965% |
| FibroGen, Inc. | 585.72 Million USD | -171.845% |
| Agilent Technologies, Inc. | 4.91 Billion USD | 67.624% |
| Corbus Pharmaceuticals Holdings, Inc. | 35.17 Million USD | -4426.437% |
| Homology Medicines, Inc. | 118.53 Million USD | -1243.314% |
| Geron Corporation | 146.12 Million USD | -989.648% |
| Alnylam Pharmaceuticals, Inc. | 4.05 Billion USD | 60.69% |
| Amicus Therapeutics, Inc. | 617.7 Million USD | -157.771% |
| Myriad Genetics, Inc. | 312.9 Million USD | -408.875% |
| Viking Therapeutics, Inc. | 20.07 Million USD | -7833.187% |
| Intellia Therapeutics, Inc. | 250.8 Million USD | -534.856% |
| Zoetis Inc. | 9.29 Billion USD | 82.87% |
| Abeona Therapeutics Inc. | 49.17 Million USD | -3137.901% |
| Mettler-Toledo International Inc. | 3.5 Billion USD | 54.578% |
| BioMarin Pharmaceutical Inc. | 1.89 Billion USD | 15.755% |
| Vertex Pharmaceuticals Incorporated | 5.14 Billion USD | 69.081% |
| Kala Pharmaceuticals, Inc. | 48.44 Million USD | -3186.758% |
| Ionis Pharmaceuticals, Inc. | 2.6 Billion USD | 38.838% |
| Atara Biotherapeutics, Inc. | 264.73 Million USD | -501.458% |
| Verastem, Inc. | 71.18 Million USD | -2136.806% |
| Nektar Therapeutics | 267.04 Million USD | -496.253% |
| Axsome Therapeutics, Inc. | 397.25 Million USD | -300.814% |
| Aclaris Therapeutics, Inc. | 40.22 Million USD | -3858.311% |
| Sarepta Therapeutics, Inc. | 2.4 Billion USD | 33.8% |
| OPKO Health, Inc. | 622.47 Million USD | -155.795% |
| Exelixis, Inc. | 678.44 Million USD | -134.694% |
| Neurocrine Biosciences, Inc. | 1.01 Billion USD | -56.197% |
| Corcept Therapeutics Incorporated | 114.81 Million USD | -1286.85% |
| Anavex Life Sciences Corp. | 12.53 Million USD | -12603.606% |
| uniQure N.V. | 624.01 Million USD | -155.164% |
| Imunon, Inc. | 8.53 Million USD | -18565.771% |
| Blueprint Medicines Corporation | 918.64 Million USD | -73.329% |
| Insmed Incorporated | 1.66 Billion USD | 4.182% |
| Halozyme Therapeutics, Inc. | 1.64 Billion USD | 3.467% |
| Agios Pharmaceuticals, Inc. | 126.09 Million USD | -1162.714% |
| TG Therapeutics, Inc. | 169.08 Million USD | -841.698% |
| Emergent BioSolutions Inc. | 1.18 Billion USD | -34.301% |